
Merck Restructures Commercial Operations Ahead of Keytruda Patent Cliff
Merck restructures commercial operations into two divisions ahead of Keytruda's 2028 patent expiration, aiming to accelerate growth from 20+ pipeline candidates.
MRKrestructuringpatent expiration